<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force</title>
	<atom:link href="http://www.xconomy.com/seattle/2010/01/04/alder-rises-from-ashes-of-layoffs-overcomes-skeptics-to-become-seattle-biotech-force/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2010/01/04/alder-rises-from-ashes-of-layoffs-overcomes-skeptics-to-become-seattle-biotech-force/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Blogosphere on Bootstrapping: Luke Timmerman &#124; Sramana Mitra on Strategy</title>
		<link>http://www.xconomy.com/seattle/2010/01/04/alder-rises-from-ashes-of-layoffs-overcomes-skeptics-to-become-seattle-biotech-force/comment-page-1/#comment-108168</link>
		<dc:creator>Blogosphere on Bootstrapping: Luke Timmerman &#124; Sramana Mitra on Strategy</dc:creator>
		<pubDate>Sat, 23 Jan 2010 09:53:13 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=56921#comment-108168</guid>
		<description>[...] I will showcase some of what they have been sending me. We start with Luke Timmerman at Xconomy : Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force:  The company, which is developing an antibody for rheumatoid arthritis and cancer, struck a deal [...]</description>
		<content:encoded><![CDATA[<p>[...] I will showcase some of what they have been sending me. We start with Luke Timmerman at Xconomy : Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force:  The company, which is developing an antibody for rheumatoid arthritis and cancer, struck a deal [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

